Speech Intelligibility of Patients With P D Compared to First Degree Relatives of P D Patients

NCT ID: NCT01776879

Last Updated: 2013-01-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-02-28

Study Completion Date

2014-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will examine speech intelligibility of early parkinson's disease (PD) patients, early PD patients and first degree relatives. The investigators hypothesis that advanced PD patients will present decreased speech intelligibility more than early PD patients. Speech intelligibility of first degree relatives will be normal.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

in order to achieve the study's goals objective and subjective research tools will be used.

Objective tools include measuring phonation time, diadokokinetic movements of the oral structures and acoustic analysis .

Subjective tools include self reported questionnaires.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson's Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

early & advanced PD 1st degree relatives

no intervention is performed in the study

No interventions assigned to this group

recording speech and voice

no intervention(s) will be administered

No interventions assigned to this group

speech intelligibility

no intervention(s) will be administered

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Advanced PD patients
* Early PD patients
* First degree relatives

Exclusion Criteria

* Patients with decreased cognitive abilities
* Patients who participate in speech therapy
Minimum Eligible Age

20 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Tel-Aviv Sourasky Medical Center

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Michal Roll PhD,MBA

director rnd devision

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Tanya Gurevich, MD

Role: PRINCIPAL_INVESTIGATOR

Tel-Aviv Sourasky Medical Center

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Tanya Gurevich, MD

Role: CONTACT

97236973061

Yael Manor, PhD

Role: CONTACT

97236973061

References

Explore related publications, articles, or registry entries linked to this study.

Amir O, Ashkenazi O, Leibovitzh T, Michael O, Tavor Y, Wolf M. Applying the Voice Handicap Index (VHI) to dysphonic and nondysphonic Hebrew speakers. J Voice. 2006 Jun;20(2):318-24. doi: 10.1016/j.jvoice.2005.08.006. Epub 2005 Dec 1.

Reference Type BACKGROUND
PMID: 16324824 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

0556-12

Identifier Type: OTHER

Identifier Source: secondary_id

TASMC-12-TG-0556-CTIL

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.